达雷妥尤单抗为基础的治疗方案在复发难治多发性骨髓瘤临床试验外患者中的疗效
该研究回顾性分析了126例接受至少1个周期以达雷妥尤单抗为基础联合治疗(DCT)的复发难治多发性骨髓瘤(RRMM)患者,中位年龄67岁,高危细胞遗传学占33%,中位既往治疗线数4线。总缓解率47%,中位无进展生存期(PFS)5.5个月。五重难治、对DCT中至少一种药物难治及既往治疗超过2线的患者PFS更差。非血液学毒性包括感染38%、疲乏32%、输注反应18%,≥3级血液学毒性41%。
要点
- 临床试验外RRMM患者接受DCT的ORR为47%,中位PFS为5.5个月。
- 五重难治患者中位PFS为2.2个月,差于四重难治(3.1个月)和其他患者(5.9个月),P<.001。
- ≥3级血液学毒性发生率为41%,感染发生率为38%。
核心结论
- DCT在RRMM中有效;但在重度预处理患者中,ORR和PFS低于临床试验报告的结果。
研究设计与样本
- 回顾性分析126例接受至少1个周期任何DCT的复发难治多发性骨髓瘤患者,中位年龄67岁(范围43-93),高危细胞遗传学占33%,中位既往治疗线数4(范围1-14),从诊断至首次DCT的中位时间4.3年(范围0.4-13.0)。
主要发现
- 总缓解率为47%,中位随访5.5个月(95%CI 4.2-6.1),中位PFS为5.5个月(95%CI 4.2-7.8),中位OS未达到(NR)。
- 五重难治MM患者(n=8)中位PFS为2.2个月(95%CI 1-2.4),四重难治MM患者(n=18)为3.1个月(95%CI 2.1-NR),其他患者(n=100)为5.9个月(95%CI 5.0-NR),P<.001。
- 对DCT中至少一种药物难治的患者中位PFS为4.9个月(95%CI 3.1-6.0),其他患者为8.2个月(95%CI 4.6-NR),P=.02。
- 既往治疗超过2线的患者中位PFS为5.0个月(95%CI 3.7-5.9),其他患者为NR(95%CI NR-NR),P=.002。
- 非血液学毒性包括感染(38%)、疲乏(32%)和输注反应(18%);≥3级血液学毒性见于41%的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Outside of clinical trials, experience with daratumumab-based combination therapies (DCTs) using bortezomib (V)/lenalidomide (R)/pomalidomide (P), and dexamethasone (d) in relapsed/refractory multiple myeloma (RRMM) is limited. We reviewed the outcomes of 126 patients who received ≥ 1 cycle of any DCT. Median age at DCT initiation was 67 (range, 43-93) years. High-risk cytogenetics was present in 33% patients. Median number of prior therapies was 4 (range, 1-14) and time to first DCT from diagnosis was 4.3 years (range, 0.4-13.0). Seventeen (13%) patients were refractory to single agent daratumumab. Fifty-two (41%), 34 (27%), 23 (18%), and 17 (14%) received DPd, DRd, DVd and "other" DCTs, respectively. Overall response rate was 47%. Median follow-up was 5.5 months (95% CI, 4.2-6.1). Median progression-free survival (PFS) was 5.5 months (95% CI, 4.2-7.8). Median overall survival was not reached (NR) with any regimen. Median PFS (months) was worst for penta-refractory MM (n = 8) vs quadruple refractory MM (n = 18) and others (n = 100) (2.2 [95% CI, 1-2.4] vs 3.1 [95% CI, 2.1-NR] vs 5.9 [95% CI, 5.0-NR]; P < .001); those who were refractory to ≥1 agents used in the DCT vs others (4.9 [95% CI, 3.1-6.0] vs 8.2 [95% CI, 4.6-NR]; P = .02); and those who received >2 prior therapies vs others (5.0 months [95% CI, 3.7-5.9] vs NR [95% CI, NR-NR]; P = .002). Non-hematologic toxicities included infections (38%), fatigue (32%), and infusion reactions (18%). Grade 3 or higher hematological toxicities were seen in 41% of patients. DCTs are effective in RRMM. ORR and PFS in heavily pretreated patients are lower than those reported in clinical trials.
引用
- Lakshman A, Abeykoon JP, Kumar SK, et al. Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials. Am J Hematol. 2017. PMID: 28799231. doi:10.1002/ajh.24883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。